Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueDepreciation & Amortization - TotalEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest ExpensesInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateTax Rate
Others
Ratios

Prestige Consumer Healthcare (PBH) Depreciation & Amortization - Total (2016 - 2025)

Prestige Consumer Healthcare has reported Depreciation & Amortization - Total over the past 15 years, most recently at $2.4 million for Q4 2025.

  • For Q4 2025, Depreciation & Amortization - Total rose 28.04% year-over-year to $2.4 million; the TTM value through Dec 2025 reached $10.4 million, up 16.75%, while the annual FY2025 figure was $9.7 million, 18.29% up from the prior year.
  • Depreciation & Amortization - Total for Q4 2025 was $2.4 million at Prestige Consumer Healthcare, down from $2.5 million in the prior quarter.
  • Over five years, Depreciation & Amortization - Total peaked at $3.9 million in Q1 2021 and troughed at $1.8 million in Q3 2021.
  • A 5-year average of $2.2 million and a median of $2.0 million in 2023 define the central range for Depreciation & Amortization - Total.
  • Biggest five-year swings in Depreciation & Amortization - Total: surged 261.34% in 2021 and later crashed 54.43% in 2022.
  • Year by year, Depreciation & Amortization - Total stood at $1.8 million in 2021, then increased by 3.6% to $1.9 million in 2022, then rose by 7.38% to $2.0 million in 2023, then decreased by 5.03% to $1.9 million in 2024, then increased by 28.04% to $2.4 million in 2025.
  • Business Quant data shows Depreciation & Amortization - Total for PBH at $2.4 million in Q4 2025, $2.5 million in Q3 2025, and $2.5 million in Q2 2025.